Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Registrati

Quotazioni in diretta

CNTA Centessa Pharmaceuticals PLC

17,98

-0,21 (-1,15%)

23 Nov 2024 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan.

Date of Notice

08/20/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/16/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Saurabh Saha

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Centessa Pharmaceuticals (NASDAQ:CNTA)
Storico
Da Ott 2024 a Nov 2024

Clicca qui per i Grafici di Centessa Pharmaceuticals

Grafico Azioni Centessa Pharmaceuticals (NASDAQ:CNTA)
Storico
Da Nov 2023 a Nov 2024

Clicca qui per i Grafici di Centessa Pharmaceuticals

Notizie Centessa Pharmaceuticals PLC - CNTA

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 22 Novembre 2024 (2 giorni fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Venerdì 22 Novembre 2024 (2 giorni fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Giovedì 21 Novembre 2024 (3 giorni fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 20 Novembre 2024 (4 giorni fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 15 Novembre 2024 (1 settimana fa) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Martedì 12 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

Form 8-K - Current report
Martedì 12 Novembre 2024 (2 settimane fa) • Edgar (US Regulatory)

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Martedì 12 Novembre 2024 (2 settimane fa) • GlobeNewswire Inc.

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Lunedì 4 Novembre 2024 (3 settimane fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 23 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 23 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martedì 22 Ottobre 2024 (1 mese fa) • Edgar (US Regulatory)

Più Centessa Pharmaceuticals PLC Articoli Notizie

Marvell Technology

Agilent Technologies

American Airlines

Anheuser Busch InBev SA NV

Credit Agricole

ACS Actividades de Const...

Koninklijke Ahold Delhai...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea